GV, Tencent and Gilead Sciences will exit the vaccine and infectious disease drug developer in an initial public offering sized at about $110m.

Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

Tencent and CapitalG-backed automation technology provider UiPath has issued approximately $200m of extra shares to close its initial public offering.

3M-backed CNS disorder therapy developer Impel priced its initial public offering in the middle of its range, giving it a $290m market cap.

SoftBank and Hanwha-backed biomanufacturer Zymergen floated at the top of its range in an upsized offering following over $870m in venture funding.

The Medtronic and Johnson & Johnson-backed epilepsy treatment system provider floated at the top of its range and saw its shares rise 47% on their first day.

University of Auckland’s Rain Therapeutics has priced shares at $17 each to raise $125m in its initial public offering.

The oat milk brand, which has filed for a $100m offering in the US, traces its origins back to Lund University in the 1990s.